BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38290657)

  • 21. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
    Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
    Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
    Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3 kinase directly phosphorylates Akt1/2 at Ser473/474 in the insulin signal transduction pathway.
    Tsuchiya A; Kanno T; Nishizaki T
    J Endocrinol; 2014 Jan; 220(1):49-59. PubMed ID: 24169049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
    Kalhori MR; Irani S; Soleimani M; Arefian E; Kouhkan F
    J Cell Biochem; 2019 Oct; 120(10):16760-16774. PubMed ID: 31243804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of nitrogen permease regulator like-2 activates PDK1-AKT1 and contributes to the malignant growth of glioma cells.
    Huang N; Cheng S; Mi X; Tian Q; Huang Q; Wang F; Xu Z; Xie Z; Chen J; Cheng Y
    Mol Carcinog; 2016 Nov; 55(11):1613-1626. PubMed ID: 26455908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
    Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y
    Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
    Zhang Z; Wang Z; Huang K; Liu Y; Wei C; Zhou J; Zhang W; Wang Q; Liang H; Zhang A; Wang G; Zhen Y; Han L
    Cancer Lett; 2019 Feb; 443():91-107. PubMed ID: 30529153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins.
    Hutz JE; Manning WA; Province MA; McLeod HL
    PLoS One; 2011; 6(9):e24873. PubMed ID: 21949775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
    Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
    PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIAA0101 knockdown inhibits glioma progression and glycolysis by inactivating the PI3K/AKT/mTOR pathway.
    Wang K; Li J; Zhou B
    Metab Brain Dis; 2022 Feb; 37(2):489-499. PubMed ID: 34792707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic and Antiproliferative Effects of β-Mangostin on Rat C6 Glioma Cells Depend on Oxidative Stress Induction via PI3K/AKT/mTOR Pathway Inhibition.
    Li K; Wu L; Chen Y; Li Y; Wang Q; Li M; Hao K; Zhang W; Jiang S; Wang Z
    Drug Des Devel Ther; 2020; 14():5315-5324. PubMed ID: 33293793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.
    Johnson SM; Gulhati P; Rampy BA; Han Y; Rychahou PG; Doan HQ; Weiss HL; Evers BM
    J Am Coll Surg; 2010 May; 210(5):767-76, 776-8. PubMed ID: 20421047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
    Tian X; Zhou D; Chen L; Tian Y; Zhong B; Cao Y; Dong Q; Zhou M; Yan J; Wang Y; Qiu Y; Zhang L; Li Z; Wang H; Wang D; Ying G; Zhao Q
    Cell Death Dis; 2018 Jan; 9(2):54. PubMed ID: 29352113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation.
    Zhao N; Guo Y; Zhang M; Lin L; Zheng Z
    Oncol Rep; 2010 May; 23(5):1443-7. PubMed ID: 20372862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Mohamed E; Kumar A; Zhang Y; Wang AS; Chen K; Lim Y; Shai A; Taylor JW; Clarke J; Hilz S; Berger MS; Solomon DA; Costello JF; Molinaro AM; Phillips JJ
    Neuro Oncol; 2022 Sep; 24(9):1471-1481. PubMed ID: 35287169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2.
    Tsutsumi K; Nohara A; Tanaka T; Murano M; Miyagaki Y; Ohta Y
    Sci Rep; 2023 Dec; 13(1):20956. PubMed ID: 38065968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway.
    Gao X; Jiang W; Ke Z; Huang Q; Chen L; Zhang G; Li C; Yu X
    Biochem Biophys Res Commun; 2022 Jan; 586():34-41. PubMed ID: 34826698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Punicic Acid Inhibits Glioblastoma Migration and Proliferation via the PI3K/AKT1/mTOR Signaling Pathway.
    Mete M; Ünsal ÜÜ; Aydemir I; Sönmez PK; Tuglu MI
    Anticancer Agents Med Chem; 2019; 19(9):1120-1131. PubMed ID: 30950355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.